JPS5989630A - 心筋梗塞治療剤 - Google Patents

心筋梗塞治療剤

Info

Publication number
JPS5989630A
JPS5989630A JP58187167A JP18716783A JPS5989630A JP S5989630 A JPS5989630 A JP S5989630A JP 58187167 A JP58187167 A JP 58187167A JP 18716783 A JP18716783 A JP 18716783A JP S5989630 A JPS5989630 A JP S5989630A
Authority
JP
Japan
Prior art keywords
urokinase
myocardial infarction
pharmaceutical composition
composition according
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58187167A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6150927B2 (OSRAM
Inventor
フランチエスコ・ポレリ
フランチエスコ・アントネテイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SpA
Original Assignee
Istituto Farmacologico Serono SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Farmacologico Serono SpA filed Critical Istituto Farmacologico Serono SpA
Publication of JPS5989630A publication Critical patent/JPS5989630A/ja
Publication of JPS6150927B2 publication Critical patent/JPS6150927B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP58187167A 1982-10-08 1983-10-07 心筋梗塞治療剤 Granted JPS5989630A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT49241A/82 1982-10-08
IT49241/82A IT1189379B (it) 1982-10-08 1982-10-08 Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico

Publications (2)

Publication Number Publication Date
JPS5989630A true JPS5989630A (ja) 1984-05-23
JPS6150927B2 JPS6150927B2 (OSRAM) 1986-11-06

Family

ID=11270058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58187167A Granted JPS5989630A (ja) 1982-10-08 1983-10-07 心筋梗塞治療剤

Country Status (12)

Country Link
US (1) US4568543A (OSRAM)
EP (1) EP0106812B1 (OSRAM)
JP (1) JPS5989630A (OSRAM)
AT (1) ATE44467T1 (OSRAM)
AU (1) AU559192B2 (OSRAM)
CA (1) CA1217717A (OSRAM)
DE (2) DE106812T1 (OSRAM)
DK (1) DK161564C (OSRAM)
ES (1) ES8704736A1 (OSRAM)
IL (1) IL69938A (OSRAM)
IT (1) IT1189379B (OSRAM)
ZA (1) ZA837484B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275812A (en) * 1985-06-07 1994-01-04 The General Hospital Corporation Method of treatment for myocardial infarction
US5279824A (en) * 1988-04-14 1994-01-18 Merck Patent Gmbh Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis
DK0456724T3 (da) * 1989-01-27 1995-10-02 Immunolytics Inc Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
CA2027936C (en) 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
EP0794779A4 (en) * 1994-12-22 1998-04-29 Smithkline Beecham Corp FIBRINOGENIC RECEPTOR ANTAGONISTS
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1179787A (en) * 1967-03-22 1970-01-28 Biorex Laboratories Ltd Stabilised and Potentiated Therapeutic Enzyme Compositions
US3708575A (en) * 1970-05-13 1973-01-02 Biorex Laboratories Ltd Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
US4271150A (en) * 1979-03-07 1981-06-02 Zeria-Shinyaku Kogyo Kabushiki Kaisha Urokinase preparation for oral administration

Also Published As

Publication number Publication date
DK464483D0 (da) 1983-10-07
IL69938A0 (en) 1984-01-31
EP0106812A3 (en) 1985-09-11
US4568543A (en) 1986-02-04
ZA837484B (en) 1984-06-27
DE3380166D1 (en) 1989-08-17
EP0106812A2 (en) 1984-04-25
IL69938A (en) 1987-09-16
EP0106812B1 (en) 1989-07-12
AU1988383A (en) 1984-04-12
CA1217717A (en) 1987-02-10
ATE44467T1 (de) 1989-07-15
IT8249241A1 (it) 1984-04-08
DK464483A (da) 1984-04-09
DK161564C (da) 1992-01-06
DK161564B (da) 1991-07-22
ES8704736A1 (es) 1987-05-01
ES526300A0 (es) 1987-05-01
DE106812T1 (de) 1984-08-30
IT1189379B (it) 1988-02-04
AU559192B2 (en) 1987-02-26
JPS6150927B2 (OSRAM) 1986-11-06
IT8249241A0 (it) 1982-10-08

Similar Documents

Publication Publication Date Title
Rosenberg et al. Studies on hemorrhagic and endotoxin shock in relation to vasomotor changes and endogenous circulating epinephrine, norepinephrine and serotonin
Lalli Contrast media reactions: data analysis and hypothesis.
WHITE et al. Experimental study on the genesis of cerebral vasospasm
US5032608A (en) Method and substrate composition for treating atherosclerosis
Mann et al. Management of the severely anemic patient who refuses transfusion: lessons learned during the care of a Jehovah's Witness
Crippen The role of sedation in the ICU patient with pain and agitation
JPH0648951A (ja) 動物あるいは人体中の心筋損傷を低下させるための薬剤
JP2000514091A (ja) 心筋症の処置
Christakis et al. Diltiazem cardioplegia: a balance of risk and benefit
JPS5989630A (ja) 心筋梗塞治療剤
CA1290692C (en) Substrate composition for treating atherosclerosis
US5248688A (en) Method and substrate composition for treating atherosclerosis
Olmstead et al. Five‐hydroxytryptamine antagonists and feline aortic embolism
Joyce et al. Coronary artery occlusion in the intact unanesthetized dog: intercoronary reflexes
US4315924A (en) Novel medicament based on aspirin and heptaminol
Dejana et al. Contribution of platelets to the cardiovascular effects of ADP in the rat
Levy et al. Effect of acute coronary artery ligation upon blood flow to the normal myocardium
Wiranowska et al. A mouse model for the study of blood-brain barrier permeability
Markland Renal artery spasm
Fischer et al. Animal model of acute pulmonary thromboembolism treated by local recirculation of streptokinase through the lung
Safar et al. Systematic search for brain resuscitation potentials after total circulatory arrest
Toung et al. Enhanced recovery of brain electrical activity by adenosine 3 prime, 5 prime-cyclic monophosphate following complete global cerebral ischemia in dogs
JPH089546B2 (ja) 抗血栓医薬組成物
CN118453510A (zh) 一种能够预防肺动脉压急性增高的载药乙醇注射液及其制备方法与应用
JPH0495031A (ja) 血栓溶解活性増強剤